Poseida Therapeutics, Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020	Q2 FY2020 As of Jun 30, 2020
Assets
Current assets:
Cash and cash equivalents
Short-term investments
Accounts receivable
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Intangible assets, net
Goodwill
Other long-term assets
Deferred offering costs
Total assets

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
Accrued expenses and other liabilities
Operating lease liabilities, current
Current portion of term debt
Deferred revenue, current
Total current liabilities

Term debt
Deferred CIRM grant liability
Warrant liability
Deferred revenue, noncurrent
Deferred tax liability
Operating lease liabilities, non-current
Other long-term liabilities
Total liabilities
Convertible preferred stock (Series A, A-1, B, C and D), $0.0001 par value: 0 and 33,085,827 shares authorized at December 31, 2020 and December 31, 2019, respectively; 0 and 32,934,785 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively
Stockholders’ equity:
Common stock, $0.0001 par value: 250,000,000 shares authorized at September 30, 2024 and December 31, 2023; 97,411,571 and 95,636,553 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively
Additional paid-in capital
Accumulated other comprehensive income
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity

Comments